A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 2, 2006, Pages 165-172

  Pilot, Henry C ^a   Adjei, Alex A ^a   Reid, Joel M ^a   Sloan, Jeff A ^a   Atherton, Pamela J ^a   Rubin, Joseph ^a   Alberts, Steven R ^a   Duncan, Barbara A ^c   Denis, Louis ^c   Schaaf, Larry J ^b   Yin, Donghua ^c   Sharma, Amarnath ^c   McGovren, Patrick ^b   Miller, Langdon L ^b   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b Pharmacia   (United States)

^c PFIZER INC   (United States)

Author keywords

Advanced solid tumors; Oral irinotecan; Pharmacokinetics; Phase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; IRINOTECAN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIAPHORESIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DYSPAREUNIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLANK PAIN; FLUSHING; HEART PALPITATION; HUMAN; LACRIMATION; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TASTE DISORDER; TENESMUS; VOMITING; WEIGHT REDUCTION;

EID: 33646472097     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0138-9     Document Type: Article

References (18)

1. Pommier Y, Tanizawa A, Kohn KW (1994) Mechanisms of topoisomerase I inihibition by anticancer drugs. In: Liu LF (ed) Advances in pharmacology. Academic, New York, pp 73-92
2. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metestatic colorectal cancer: irinotecan study group. New Engl J Med 343:905-914
3. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041-1047
4. Drengler RL, Kuhn JG, Schaaf LJ et al (1999) Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685-696
5. Simon RM, Friedlin B, Rubinstein LV et al (1997) Accelerated titration designs for Phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147
6. Slatter JG, Schaaf LJ, Sams JP et al (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (irinotecan) following intravenous infusion of [(14)C]irinotecan in cancer patients. Drug Metab Dispos 28:423-433
7. Gibaldi M, Perrier D (1982) Non-compartmental analysis based on statistical moment therapy. In: Gibaldi M, Perrier D (eds) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 409-417
8. Rothenberg ML, Kuhn JG, Burris HA et al (1993) Phase I and pharmacokinetic trial of weekly irinotecan. J Clin Oncol 11:2194-2204
9. Rougier P, van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412
10. Liu G, Franssen E, Fithc MI et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115
11. Borner MM, Schoffski P, de Wit R et al (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349-358
12. Rowinsky EK, Grochow LB, Ettinger DS et al (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (irinotecan) administered as a ninety-minute infusion every three weeks. Cancer Res 54:427-436
13. Abigerges D, Chabot GG, Armand JP et al (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221
14. Chabot GG, Abigerges D, Catimel G et al (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (irinotecan) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151
15. Rivory LP, Riou JF, Haaz M-CH et al (1996) Identification and properties of a major metabolite of irinotecan (irinotecan) isolated from the plasma of patients. Cancer Res 56:3689-3695
16. Pitot HC, Goldberg RM, Reid JM et al (2000) Phase I dose finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6:2236-2244
17. Gupta E, Lestingi TM, Mick R et al (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725
18. Schaaf L, Ichhpurani N, Elfring G et al (1997) Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G) in patients with previously treated colorectal cancer (abstract). Proc Am Soc Clin Oncol 16:202a